lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

The Clinical Characteristics of Myocardial Injury in Severe and Very Severe Patients with 2019 Novel Coronavirus Disease

19 Pages Posted: 19 Feb 2020

See all articles by Bo Zhou

Bo Zhou

Xi'an Jiaotong University (XJTU) - Department of Respiratory Medicine

Jianqing She

Xi'an Jiaotong University (XJTU) - Cardiovascular Department

Yadan Wang

Huazhong University of Science and Technology - Institute of Hematology

Xiancang Ma

Xi'an Jiaotong University (XJTU) - Department of Psychiatry

More...

Abstract

Background: Despite previous studies discussing the clinical and epidemiological features of 2019 Novel coronavirus disease (COVID-19), few have investigated the alteration of cardiac lesion markers and how it is correlated to disease severity. This study aims to describe the clinical characteristics of myocardial injury in severe and very severe COVID-19 patients.

Methods: We enrolled in-hospital patients with COVID-19 admitted to the West District of Union Hospital of Tongji Medical College in the 7th floor ward from February 5th to February 13rd, 2020. Demographic data were collected upon admission. Laboratory confirmation of COVID-19, blood count, creatine, liver enzymes, and cardiac lesion markers were together tested by the laboratory department.

Findings: 34 patients with COVID-19 were included in this study, 8 patients met the criteria for very severe COVID-19, and 26 for severe COVID-19. The median age was 63yrd (inter quartile range {IQR}:58-69) among severe COVID-19 group and 67yrd (IQR: 66-75) among very severe group. We noted significantly increased cTnI (46.8ng/L [IQR: 34.2-299.8] vs. 4.8ng/L [IQR: 34.2-299.8]), CK (199U/L [IQR: 77-285] vs. 88U/L [IQR: 45-125]), HBDB (453U/L [IQR: 347-547] vs. 245U/L [IQR: 207-275]) and LDH (513U/L [IQR: 414-641] vs. 287U/L [IQR: 246-331]) in very severe group as compared to severe group. Importantly, the percentage of very severe patients with elevated cTnI levels was markedly higher, with 8/8 patients exhibiting increased cTnI in very severe group, and only 1/26 patient in severe group (P value<0.001).

Interpretation: We have found high percentage of increased cTnI levels in very severe COVID-19. Protecting from myocardial injury could be of vital importance for reducing the mortality rate in very severe COVID-19.

Funding Statement: This study was funded by the Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University, China (No.XJTU1AF-CRF-2018-025).

Declaration of Interests: The authors declare no competing interests.

Ethics Approval Statement: The study was approved by the ethics committee of the local hospital and data were collected retrospectively.

Keywords: Clinical characteristics, COVID-19, cTnI, myocardial injury, severe and very severe patients

Suggested Citation

Zhou, Bo and She, Jianqing and Wang, Yadan and Ma, Xiancang, The Clinical Characteristics of Myocardial Injury in Severe and Very Severe Patients with 2019 Novel Coronavirus Disease (2/16/2020). Available at SSRN: https://ssrn.com/abstract=3539668 or http://dx.doi.org/10.2139/ssrn.3539668

Bo Zhou

Xi'an Jiaotong University (XJTU) - Department of Respiratory Medicine

China

Jianqing She

Xi'an Jiaotong University (XJTU) - Cardiovascular Department ( email )

Shaanxi
China

Yadan Wang

Huazhong University of Science and Technology - Institute of Hematology ( email )

Wuhan
China

Xiancang Ma (Contact Author)

Xi'an Jiaotong University (XJTU) - Department of Psychiatry ( email )

26 Xianning W Rd.
Xi'an, Shaanxi 710049
China